Finding ED90 of Flumazenil for Selective Improvement of Respiratory Distress by Remimazolam

NACompletedINTERVENTIONAL
Enrollment

60

Participants

Timeline

Start Date

August 23, 2023

Primary Completion Date

December 1, 2023

Study Completion Date

December 1, 2023

Conditions
Stomach Neoplasm
Interventions
DRUG

Flumazenil

The dose determination for flumazenil followed a biased-coin up-and-down design. Starting with an initial dose of 5 mcg, if there was an improvement in respiratory distress, the biased-coin method was used to give the same dose in the next patient with a probability of 8/9, and a decreased dose of 5 mcg in the next patient with a probability of 1/9.

Trial Locations (1)

Unknown

Severance hospital, Seoul

All Listed Sponsors
lead

Yonsei University

OTHER

NCT06563063 - Finding ED90 of Flumazenil for Selective Improvement of Respiratory Distress by Remimazolam | Biotech Hunter | Biotech Hunter